Prenetics Global Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $340.1M
- Price
- $20.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +12.47%
- Volume
- 309.8K
About
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Quick stats
Shares outstanding16.8M
Computed float13.6M
Float / shares80.7%
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001876431
Websitehttps://www.prenetics.com
AI Summary
AI-generated1/32
standardbullishpartnership
Prenetics’ IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Prenetics announced a multi-year partnership with two-time Golden Globe-nominated actress Lily Collins, who becomes a Global Ambassador and shareholder for its IM8 brand.
Collins brings over 33 million social media followers and an engagement rate of 5.9%, expanding IM8’s reach beyond elite sports into global entertainment and female demographics.
Driven by IM8's growth, Prenetics raised FY 2026 revenue guidance to $220–$230 million and initiated FY 2027 guidance of $400+ million, noting it achieved positive Adjusted Free Cash Flow in July 2026.